Arcadia Biosciences IncRKDA
Price$0.28

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $4.7M-5.9% YoYTTM through 30 Jun 2026
Net Income -$11.1MTTM through 30 Jun 2026
Free Cash Flow -$2.5MTTM through 30 Jun 2026

Margins

Current
Gross Margin36.4%
EBITDA Margin-75.5%
Operating Margin-70.8%
Net Margin-234.5%

Returns

-321.8%ROE
-174.4%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio3.79x
Net Debt-$3.7Mnet cash position
Cash & Equivalents$4.2M

Quality Metrics

Altman Z-Score-69.71
Piotroski F-Score1 / 9
FCF Margin-53.2%
Earnings-Beat Rate50.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $4.9M
Diluted EPS
'21'22'23'24'25
FY2025: $-1.71

Dividend

No dividend

Capital Allocation

R&D Spend$0
Capex Intensity0.5%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.